Breast Cancer

Following a Type A meeting with the FDA to discuss deficiencies raised in a complete response letter pertaining to the new drug application for the use of oral paclitaxel encequidar in patients with metastatic breast cancer, the biopharmaceutical company Athenex, Inc. announced that their resources will be redeployed to focus on other studies examining oral paclitaxel.

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Zahi Mitri, MD, MS, discusses recent advancements made across the breast cancer paradigm and spotlighted key data that led to the integration of novel agents into the armamentariums.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.

Nadia Harbeck, MD, PhD, discusses the key results from the phase 2 WSG ADAPT-TP trial in patients with HER2-positive, hormone receptor–positive early-stage breast cancer.

Zahi Mitri, MD, MS, discusses developments in the treatment of patients with HER2-positive breast cancer.

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Dawn Hershman, MD, a leading breast cancer physician-scientist and pioneer in the burgeoning field of cancer care delivery research, has been named to the Giants of Cancer Care Class of 2021.